Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer

Inclusion Criteria

• Diagnosis of ovarian epithelial or primary peritoneal cavity cancer
• Relapsed disease
• Persistent disease
• Platinum-resistant disease, defined as having evidence of disease that would be expected to be non-responsive to additional platinum-containing regimens or contraindication to platinum-based chemotherapy and 1 of the following:
• Failure to obtain a complete response to initial platinum therapy
• Recurrence 40% by ECHO for patients with prior anthracycline therapy
• No significant cardiac disease including any of the following:
• New York Heart Association class III or IV heart disease
• History of myocardial infraction within the past year
• Uncontrolled dysrhythmias or requirement for antiarrhythmic drugs
• Poorly controlled angina
• No history of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row)
• No history of QTc ≥ 500 msec
• No active ischemic heart disease within the past 12 months
• No congenital long QT syndrome
• No left bundle branch block
• No cardiac symptoms ≥ grade 2
• No history of cardiac toxicity after receiving anthracyclines (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, mitoxantrone, bleomycin, or carmustine)
• Does not meet the medicare criteria for home oxygen
• No pulse oximetry at rest and exercise 25% of bone marrow
• No history of radiotherapy that potentially included the heart in the field (e.g., mantle)
• Chest wall irradiation or other radiotherapy techniques that do not include the heart in the radiation field area allowed
• More than 4 weeks since prior radiotherapy
• More than 4 weeks since prior radiopharmaceuticals
• No concurrent radiotherapy
• No other concurrent investigational therapy
• No concurrent medications that may prolong QTc